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Immunotherapy has emerged as a promising and effective treatment for cancer, yet the clinical 
benefit is still variable, in part due to insufficient accumulation of immune effector cells in the tumour 
microenvironment. Better understanding of tumour-infiltrating lymphocytes (TILs) from nonhuman 
primate tumours could provide insights into improving effector cell accumulation in tumour tissues 
during immunotherapy. Here, we characterize TILs in a cynomolgus macaque tumour model in which 
the tumours were infiltrated with CD4+ and CD8+ T cells and were eventually rejected. The majority of 
CD4+ and CD8+ TILs exhibited a CD45RA−CCR7− effector memory phenotype, but unlike circulating T 
cells, they expressed CD69, a marker for tissue-resident memory T (TRM) cells. CD69-expressing CD8+ 
TILs expressed high levels of the cytotoxic molecule granzyme B and the co-inhibitory receptor PD-1. 
Consistent with the TRM cell phenotype, CD8+ TILs minimally expressed CX3CR1 but expressed CXCR3 at 
higher levels than circulating CD8+ T cells. Meanwhile, CXCL9, CXCL10 and CXCL11, chemokine ligands 
for CXCR3, were expressed at high levels in the tumours, thus attracting CXCR3+CD8+ T cells. These 
results indicate that tumour-transplanted macaques can be a useful preclinical model for studying and 
optimizing T cell accumulation in tumours for the development of new immunotherapies.
Increasing evidence has demonstrated the important role of the immune system in controlling tumour develop-
ment1,2. Strategies harnessing the immune system to treat cancer have made great advances in recent years3. These 
immunotherapies include cancer vaccines, immune checkpoint inhibitors and adoptive cell therapy. The success-
ful use of immune checkpoint inhibitors, which target CTLA-4 and the PD-1/PD-L1 axis, has brought hope for 
cure in several types of cancer4. In addition, adoptive transfer of naturally occurring or genetically engineered T 
cells has shown promise in some malignancies5. The development of these immune-based antitumour therapies 
necessitates an animal model with an immune system similar to that of humans. Although mouse tumour models 
have provided important insights into antitumour immune responses, substantial differences between the mouse 
and human immune systems hamper the clinical translation of the results obtained in mouse tumour models6. 
Thus, tumour models utilizing nonhuman primates, which are phylogenetically closer to humans than any other 
laboratory animals, are required for the development and optimization of new immunotherapies7.
The clinical success of all immunotherapies relies on the efficient migration and localization of immune 
effector cells, whether endogenous or adoptively transferred, to tumour target tissue8. This issue is critical when 
immunotherapies are targeted to solid tumours. Tumour-infiltrating lymphocyte (TIL) populations can be iso-
lated from various tumours, and CD8+ T cells (cytotoxic T cells; CTLs) are the major subset of TILs that mediate 
tumour regression. It is becoming clear that TILs share phenotypic characteristics with tissue-resident memory 
T (TRM) cells, a recently discovered lineage of T cells that remain in tissues without recirculating through the 
blood9. TRM-like TILs can be found in various human tumours and mouse models, and the presence of these TILs 
is associated with a favourable prognosis10.
A critical step in the generation of tumour-associated TRM cells is the trafficking of T cells into the tumour. 
Immune effector cell trafficking to the tumour microenvironment is a highly dynamic process involving a series 
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of distinct steps that include rolling, adhesion, extravasation and migration within the tissue11. These steps are pri-
marily mediated by adhesion molecules and chemokines. Many cancers have a complex network of chemokines 
and their receptors, which is a key determinant of TIL accumulation at the tumour site12. CXCR3 and its ligands 
CXCL9 and CXCL10 have been implicated in CTL infiltration into several types of cancer and are positively cor-
related with a better prognosis13–16. In addition to CXCR3, CCR1, CCR4 and CCR5 have been implicated in T cell 
infiltration to the tumour site17. As effective immunotherapy requires that CTLs physically contact tumours cells, 
chemokine–chemokine receptor expression profiles that determine CTL migratory behaviour can be exploited to 
develop immunotherapies with enhanced efficacy. However, CTL migratory profiles in nonhuman primates, such 
as rhesus and cynomolgus macaques, have not been reported.
We previously established a novel tumour transplantation model in cynomolgus macaques, in which induced 
pluripotent stem cell (iPSC)–derived tumour cells carrying a homozygous major histocompatibility complex 
(MHC) haplotype were injected into MHC-matched macaques18. Although these cells formed tumours when 
injected into immunodeficient NOG mice, they were immunologically rejected in MHC-matched macaques 
within 4–5 weeks. Thus, this model may be useful for analysing TILs that generally play major roles in the immu-
nological rejection of tumours and optimizing the efficacy of new immunotherapies.
In this study, we report the characterization of TILs in this iPSC-derived tumour transplantation macaque 
model. CD8+ TILs that accumulated at the tumour site had TRM-like phenotypes and expressed high levels of 
CXCR3, and the tumour expressed CXCR3 ligands, mirroring the characteristics of TILs in human cancers. Thus, 
this macaque model proves useful for analysing and optimizing T cell trafficking and localization to the tumour 
site in the development of new immunotherapies.
Results
CD4+ and CD8+ T cells are preferentially recruited from blood into the tumour in a macaque 
tumour model. We previously established tumour cell lines from iPSCs of a cynomolgus macaque carrying a 
homozygous MHC haplotype18. When these tumour cells, named PTY cells, were transplanted into cynomolgus 
macaques heterozygous for the matched MHC haplotype, they were rejected within 4–5 weeks. The involvement 
of humoral immunity as a mechanism of tumour rejection has been shown previously18, but the role of TILs in 
this model has not been investigated. TILs, together with various types of immune cells and stromal cells, con-
tribute to the formation of a complex tumour microenvironment, which regulates tumour progression19,20. We 
first examined the peripheral blood (PB) lymphocyte compartment after tumour transplantation in comparison 
with TILs. PTY cells were injected into four separate regions of the backs of two macaques heterozygous for the 
matched MHC haplotype at day 0, and the generated tumours were surgically removed at day 14 before they 
were rejected. We monitored PB until day 28. Flow cytometric analysis revealed that during this time period, 
there were no apparent changes in total leukocyte and lymphocyte numbers of the first tumour-transplanted 
macaque (Fig. 1a). A slight increase in CD20+ B cells was observed at days 14 and 28 (Fig. 1b, the uppermost 
panel, and c). Within CD3+ T cell populations, CD4+CD8− cells (CD4+ T cells), CD4−CD8+ cells (CD8+ T cells) 
and CD4+CD8+ double-positive T cells (DP T cells) were identified (Fig. 1b, the second upper panel). As reported 
previously21, DP T cells were found at a considerable percentage in cynomolgus macaque blood. The number of 
these T cell subsets did not change appreciably after tumour transplantation (Fig. 1c). As reported for the blood 
of rhesus macaques22, natural killer (NK) cells were identified as CD8+CD16+ and CD8+CD16− cells within the 
CD3−CD20− population and as CD8+CD16− cells within the CD3−CD20dim population (Fig. 1b, the bottom two 
panels). All of these NK cell subsets showed an increase in number at day 14 post injection (Fig. 1d).
To examine the composition of TIL populations in this model, single-cell suspensions were prepared from 
the tumour resected at day 14 post injection and were analysed by flow cytometry for the same markers used in 
the PB analysis (Fig. 1b). Most of the infiltrated lymphocytes were CD3+ T cells, while CD20+ B cells were found 
only marginally (Fig. 1e). Among T cell populations, CD4+ and CD8+ T cells were the major subsets. DP T cells 
were also found in the tumour, albeit less frequently than in PB. These results suggested that among the three 
circulating T cell populations, CD4+ and CD8+ T cells were preferentially recruited from blood into the tumour 
microenvironment. Similar results were obtained from the PB and tumour of the second tumour-transplanted 
macaque (Supplementary Fig. 1). Additionally, NK cells of the CD8+CD16−CD20− phenotype were found in a 
considerable number in the tumour (Fig. 1e).
The majority of CD4+ and CD8+ TILs express the TRM marker CD69. Because CD4+ and CD8+ T 
cells were the subsets most abundantly infiltrated in the tumour, we further examined these T cell compartments. 
Human CD4+ and CD8+ T cells in the blood and secondary lymphoid organs can be separated into four function-
ally different populations based on the expression of CD45RA and CCR7: naive (TN; CD45RA+CCR7+), central 
memory (TCM; CD45RA−CCR7+), effector memory (TEM; CD45RA−CCR7−) and effector memory re-expressing 
CD45RA (TEMRA; CD45RA+CCR7−)23. Similarly, the four populations were identified for both CD4+ and CD8+ 
T cell compartments in macaque blood (Fig. 2a). In the CD4+ T cell compartment in the blood, the percentage 
and number of TCM and TEM cells were increased at day 14, and these two subsets primarily constituted the CD4+ 
TILs (Fig. 2b). Among CD8+ T cell populations in the blood, TEM and TEMRA cells were increased at day 14 both 
in percentage and number, and these were the major subsets found in the tumour (Fig. 2c). For both CD4+ and 
CD8+ TILs, TEM cells were the more abundant subset.
It has been shown that a subset of memory T cells does not recirculate but is maintained in peripheral tissues. 
Increasing evidence indicates that such TRM cells accumulate in various human cancer tissues and constitute 
a substantial population of TILs10. Indeed, in this macaque model, CD69, a marker for TRM cells, was barely 
expressed in circulating CD4+ and CD8+ T cells but was expressed in 56% and 64% of CD4+ and CD8+ TILs, 
respectively (Fig. 2d). Although CD69 is also a classical early marker of lymphocyte activation, CD69 expression 
on TILs was retained after culture with low-dose IL-2 (Supplementary Fig. 2), suggesting that CD69+ TILs are 
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TRM cells rather than early-activated lymphocytes. CD69-expressing cells were more frequently found in the TEM 
subset than in the other subset for both CD4+ and CD8+ TILs (Fig. 2e). These results indicate that CD4+ and 
CD8+ TRM-like cells accumulated in the tumour tissue in this model.
tRM-like CD8+ TILs express high levels of granzyme B. To characterize the functional properties of 
TILs in this macaque tumour model, we sorted CD4+ and CD8+ T cells from the tumour tissue as well as from 
PB and quantified the mRNA levels of cytokines in these populations. In both CD4+ and CD8+ TILs, IFN-γ was 
markedly increased compared to that in blood CD4+ and CD8+ T cells, respectively, suggesting that TILs contain 
IFN-γ–producing TH1 cells and CTLs (Fig. 3a). IL-17A, a cytokine produced primarily by TH17 cells, was also 
remarkably increased in CD4+ TILs. CD8+ TILs also expressed IL-17A, albeit less than CD4+ TILs. Intracellular 
cytokine staining also showed that CD8+ TILs contained more IFN-γ–producing cells and IL-17A–producing 
cells than blood CD8+ T cells (Fig. 3b). In addition to inflammatory cytokines, the anti-inflammatory cytokine 
Figure 1. CD4+ and CD8+ T cells are the major TIL subsets in a cynomolgus macaque tumour model. (a) 
Total leukocyte and lymphocyte counts. Blood was obtained at days 0, 14 and 28 after tumour transplantation 
and analysed by flow cytometry. Live cells were gated as 7-AAD−. Leukocytes were determined as CD45+, 
and lymphocytes were gated according to forward and side scatter from the CD45+ cells. (b) Flow cytometry 
plots for the analysis of lymphocyte subsets in PB and tumour tissue. The tumour was resected at day 
14 after transplantation. B cells (CD3−CD20+), CD4+ T cells (CD3+CD20−CD4+CD8−), CD8+ T cells 
(CD3+CD20−CD4−CD8+) and DP T cells (CD3+CD20−CD4+CD8+) were identified. Three subsets of NK 
cells were identified as CD3−CD20−CD8+CD16+, CD3−CD20−CD8+CD16− and CD3−CD20dimCD8+CD16−. 
Numbers adjacent to the outlined areas indicate the percentage of cells in each. (c) Number of B cells, CD4+ 
T cells, CD8+ T cells and DP T cells in PB. (d) Number of the three NK cell subsets in PB. (e) Number of TIL 
populations in the tumour resected at day 14. The number of cells per gram tumour is shown.
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IL-10 was expressed at a high level specifically in CD4+ TILs (Fig. 3a), suggesting that CD4+ TILs contain a pop-
ulation of regulatory T cells.
Infiltrated CTLs express several cytotoxic molecules such as perforin and granzyme B, which lyse tumour 
cells. In this macaque model, CD8+ TILs showed much higher expression levels of perforin and granzyme B 
compared to CD8+ T cells in the blood (Fig. 3c). Flow cytometric analysis of CD8+ TILs revealed that TEM cells, 
particularly CD69-expressing TRM-like cells, expressed high levels of granzyme B (Fig. 3d). CD8+ TILs often 
express high levels of the co-inhibitory receptor PD-1, and the expression status of PD-1 on TILs predicts the 
response to anti–PD-1 therapy24,25. Quantitative PCR analysis revealed that PD-1 mRNA expression was signifi-
cantly increased in CD8+ TILs compared to blood CD8+ T cells (Fig. 3c). Among CD8+ TILs, TEM cells expressed 
higher levels of PD-1 than TEMRA cells, and the CD69-expressing subset contained cells with the highest levels of 
PD-1 (Fig. 3d). Taken together, these results suggested that the CD8+ TILs with the TRM-like phenotype showed 
the highest cytotoxic properties, although they also expressed high amounts of PD-1. Additionally, the DP T cell 
subset in the tumour, which comprised primarily of TEM and CD69-expressing cells, contained cells with high 
levels of granzyme B (Supplementary Fig. 3), suggesting that TRM-like DP T cells also have cytotoxic properties.
CXCR3 and its ligands are upregulated in the tumour microenvironment. The chemokine–chemok-
ine receptor system is one of the major factors governing the trafficking of immune cells from blood to tissues, includ-
ing tumour tissue12. To explore the chemokines and chemokine receptors involved in T cell trafficking from blood to 
the tumour in this macaque model, we quantified the mRNA levels of all known chemokine receptors in CD4+ and 
CD8+ T cells sorted from the tumour tissue and PB. CCR2, CCR3, CCR5, CXCR3 and CXCR4 were upregulated in 
CD4+ TILs compared to blood CD4+ T cells, while CCR7, CCR9, CCR10 and CX3CR1 were downregulated (Fig. 4a). 
CXCR3 and CXCR4 were upregulated in CD8+ TILs compared to blood CD8+ T cells at day 14, with CXCR3 showing 
more prominent upregulation than that in CD4+ T cells. Similar to CD4+ TILs, CCR7, CCR9, CCR10 and CX3CR1 
were markedly downregulated in CD8+ TILs compared to blood CD8+ T cells. The low CCR7 mRNA levels were in 
agreement with the small percentage of CCR7+ TN and TCM cells in both CD4+ and CD8+ TILs (Fig. 2a–c). Flow cyto-
metric analysis showed that CXCR3 was expressed on CD8+ TILs at slightly higher levels on TEM than TEMRA cells, 
while similar CXCR3 expression levels were observed between CD69+ and CD69− cells (Fig. 4b).
Figure 2. The majority of TILs are of the TEM phenotype and express CD69. (a) Expression of CCR7 and 
CD45RA in CD4+ and CD8+ T cells from PB and tumour tissue. Blood was obtained at days 0, 14 and 28, and the 
tumour was resected at day 14 after tumour transplantation. The TN, TCM, TEM and TEMRA subsets were determined 
as CD45RA+CCR7+, CD45RA−CCR7+, CD45RA−CCR7− and CD45RA+CCR7−, respectively, for both CD4+ 
and CD8+ T cells. Numbers in quadrants indicate the percentage of cells in each. (b) Percentage and number of 
TN, TCM, TEM and TEMRA subsets in CD4+ T cells from PB and tumour tissue. (c) Percentage and number of TN, 
TCM, TEM and TEMRA subsets in CD8+ T cells from PB and tumour tissue. (d) Expression of CD69 in CD4+ and 
CD8+ T cells from PB and tumour tissue. Numbers adjacent to the outlined areas indicate the percentage of cells 
in each. (e) Expression of CD69 in CD4+ TEM and TCM cells and in CD8+ TEM and TEMRA cells from tumours.
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We next examined the mRNA expression of chemokines in the tumour tissue and compared the mRNA levels 
with those in cultured PTY cells and in the skin before tumour injection. Among the chemokine ligands tested, 
the CCR5 ligands CCL3 and CCL5 were remarkably upregulated in the tumour tissue compared to PTY cells 
or control skin (Fig. 4c). CCL5 is also a ligand for CCR3. Thus, the CCL3/CCL5–CCR5 and CCL5–CCR3 axes 
appear to play a role in CD4+ T cell infiltration in the tumour. In contrast, the CCR7 ligand CCL21 was expressed 
at a lower level than the control skin, which was in agreement with the low expression of CCR7 in both CD4+ 
and CD8+ TILs. The CXCR3 ligands CXCL9, CXCL10 and CXCL11 were all elevated in the tumour, suggesting 
that the CXCL9/CXCL10/CXCL11–CXCR3 axis is involved in both CD4+ and CD8+ T cell infiltration into the 
tumour. The CXCR4 ligand CXCL12 and the CX3CR1 ligand CX3CL1 were downregulated in the tumour tissue.
Repeated tumour injection induces rapid loss of CXCR3high CD8+ T cells in the blood. When PTY 
cells were injected into a cynomolgus macaque for the first time, they were rejected within 4–5 weeks. However, 
repeated tumour cell injection into the same individual induced rapid tumour rejection without tumour growth, 
suggesting that tumour-specific lymphocytes had been expanded and were rapidly recruited from blood to the 
tumour injection site. To explore the involvement of CXCR3 in this repeated injection model, we examined PB 
by flow cytometry. The lymphocyte number in the blood was decreased at 48 h post injection (Fig. 5a), and both 
CD4+ and CD8+ T cell numbers were decreased (Fig. 5b). CD4+ and CD8+ T cell compartment analysis revealed 
that CD4+ TCM and TEM cells, the major subsets of CD4+ TILs, as well as CD8+ TEM and TEMRA cells, the major 
subsets of CD8+ TILs, were decreased at 48 h post injection (Fig. 5c,d). Compared to that in naive macaques, the 
CD8+ TEM cell subset was remarkably expanded in the blood of the repeated injection model, and this subset 
was the one most substantially decreased at 48 h post injection. At this time point, CXCR3 expression in CD8+ 
TEM and TEMRA cells was appreciably decreased (Fig. 5e,f), suggesting that CXCR3high cells had migrated into the 
tumour injection site. Together, these results support the view that CXCR3 plays a role in T cell migration into the 
tumour tissue in this macaque tumour model.
Discussion
In this study, we showed that a nonhuman primate tumour model, in which iPSC-derived tumour cells were 
transplanted into MHC-matched macaques, represents a useful animal model for studying TILs. Chemokine–
chemokine receptor expression profiles in TILs and tumour locales in this macaque model share many features 
with those reported for human cancers, rendering this model useful for preclinical studies that aim to optimize 
immune effector cell trafficking to the tumour site.
Figure 3. CD8+ TILs express high levels of cytotoxic molecules and PD-1. (a) Relative mRNA expression of 
IFN-γ, IL-17A and IL-10 in CD4+ and CD8+ T cells isolated from PB and tumour tissue. Blood was obtained 
at days 0, 14 and 28, and the tumour was resected at day 14 after tumour transplantation. The mRNA levels 
were assessed by real-time PCR and are presented relative to β-actin levels. (b) Intracellular staining for IFN-γ 
and IL-17A in CD8+ T cells from PB and tumours. Blood and the tumour were obtained at day 14. (c) Relative 
mRNA expression of perforin, granzyme B and PD-1 in CD8+ T cells isolated from PB and tumour tissue. The 
mRNA levels were assessed as in (a). (d) Flow cytometric analysis of the expression of granzyme B and PD-1 in 
CD8+ T cells and CD8+ TEM cells from tumours.
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The chemokine–chemokine receptor system is a key regulator of TIL accumulation in the tumour environ-
ment12. We found that CD8+ TILs exhibited higher expression levels of CXCR3 compared to circulating CD8+ T 
cells. CXCL9, CXCL10 and CXCL11, chemokine ligands for CXCR3, were expressed at high levels in the tumour 
locale. These results are consistent with a recent report that CXCR3 is the major chemokine receptor required 
for CD8+ T cell migration into mouse and human melanoma15. Previously, CXCR3 expression in activated CD8+ 
T cells was reported to be associated with enhanced survival in melanoma patients with stage III disease13. In 
a mouse model of melanoma, CXCR3 deficiency attenuates the infiltration of CD8+ T cells into tumours and 
thereby reduces antitumour immunity26. CXCL9 and CXCL10 expression is associated with survival in human 
colorectal cancer14 and exerts tumour suppressive function by TIL recruitment in ovarian cancer16.
Accumulating evidence indicates that a substantial population of CD8+ TILs are TRM-like cells10. These 
TRM cells have been identified by surface expression of CD103 and CD69 in both humans and mice. Indeed, 
Figure 4. CXCR3 and its ligands are upregulated in the tumour microenvironment. (a) Relative mRNA 
expression of chemokine receptors in CD4+ and CD8+ T cells isolated from PB and tumour tissue. The mRNA 
levels were assessed by real-time PCR and are presented relative to β-actin levels. (b) Flow cytometric analysis of 
CXCR3 expression in CD8+ T cells and CD8+ TEM cells from tumours. (c) Relative expression of chemokines in 
cultured PTY cells, skin and tumour. The mRNA levels were assessed as in (a).
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the majority of CD8+ TILs in this macaque model expressed CD69. CD69 downregulates the sphingosine 
1-phosphate receptor S1PR1, which is required for T cell egress from tissues and thus promotes tissue resi-
dency27,28. On the other hand, CD103 binds to the epithelial cell marker E-cadherin, thereby promoting T cell 
residency in epithelial tumours and antitumour CTL function29,30. In our model, CD103 expression was not 
detected in CD8+ TILs, which is likely due to the non-epithelial nature of PTY tumour cells. Human TRM cells 
infiltrating the lungs express CXCR3, CXCR6 and CCR6 at higher levels compared to blood TEM cells31, while in 
our macaque tumour model, CXCR3 but not CXCR6 or CCR6 was upregulated in CD8+ TILs. Consistent with 
the low expression of CX3CR1 mRNA in human TRM cells, CX3CR1 expression was remarkably downregulated 
in CD8+ TILs in the macaque tumour model.
In recent years, immune checkpoint blockade has been revolutionizing cancer therapy. PD-1 inhibitors, such 
as nivolumab and pembrolizumab, have been approved for use in the treatment of melanoma and non-small cell 
lung cancer32. In the tumour microenvironment, the PD-1 and PD-L1 interaction supports tumour development 
by negatively regulating immune responses. PD-1 inhibitors block this interaction, leading to more robust T cell 
activity and improved prognosis. The decreased efficacy of PD-1 inhibitor treatment in CXCR3-deficient mice 
suggests that CXCR3-expressing CD8+ TILs are the responder cells in anti–PD-1 therapy26. In our macaque 
model, PD-1 expression was higher in CD8+ TILs compared to blood CD8+ T cells, and within the CD8+ TILs, 
CD69-expressing TRM-like cells expressed higher levels of PD-1 than CD69− cells.
Although we focused mostly on CD4+ and CD8+ T cells in this paper, DP T cells and NK cells also infiltrated 
the tumour in this model. DP T cells in cynomolgus macaque blood are known to be CD8α+β− extrathymic 
T cells21. In our analysis, blood DP T cells were mostly TEMRA cells, but similar to CD4+ and CD8+ TILs, DP 
T cells in the tumour comprised primarily of TEM cells. Interestingly, DP T cells in the tumour contained cells 
with high cytotoxic properties, suggesting that these cells also contributed to tumour rejection in this model. 
In this regard, DP T cells in cynomolgus macaque blood have cytotoxic activity comparable to that of CD8+ T 
cells33. NK cells infiltrating the tumour in this model were mostly of the CD8+CD16−CD20− phenotype, while 
CD8+CD16+CD20− NK cells were dominant in blood. Similarly, in human melanoma patients, CD56dimCD16− 
cells are the dominant subset in tumour-infiltrating NK cells, while CD56dimCD16+ cells are dominant among 
circulating NK cells34. It is conceivable that NK cells also play a role in tumour rejection in this model.
Figure 5. Repeated tumour injection induces rapid loss of CXCR3high CD8+ T cells from blood. (a) Total 
leukocyte and lymphocyte counts in PB of a macaque repeatedly injected with tumour cells. Blood was obtained 
at 0, 24 and 48 h after tumour injection. (b) Number of lymphocyte subsets in PB. (c) Number of TN, TCM, TEM 
and TEMRA cells in CD4+ T cells from PB. (d) Number of TN, TCM, TEM and TEMRA cells in CD8+ T cells from 
PB. (e) Expression of CXCR3 on CD8+ TN, TEM and TEMRA cells in PB. (f) Time course of mean fluorescence 
intensity (MFI) of CXCR3 expression on CD8+ TN, TEM and TEMRA cells in PB.
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Adoptive immunotherapy using naturally occurring or gene-engineered tumour-specific T cells also offers a 
promising cancer therapy. In particular, chimeric antigen receptor (CAR) T cells have been proven to serve as a power-
ful new class of adoptive immunotherapeutics. Adoptive immunotherapy for solid tumours requires that T cells traffic 
to the tumour tissue. Although T cell trafficking has been extensively studied in mouse tumour models, extrapolation 
of mouse data to humans is limited due to differences between the mouse and human immune systems6. Humanized 
mouse models can produce some of the human immune responses, yet they still cannot replicate the entire human 
immune response to tumours. Moreover, tumours develop in complex microenvironments that regulate tumour pro-
gression and metastasis and in turn the efficacy of immunotherapy. Nonhuman primates have immunologically closer 
microenvironments to human cancers than any other animal tumour model and thus can provide relevant models for 
testing the efficacy of antitumour therapies7. The understanding of chemokine receptor expression patterns of CD8+ 
TILs in macaque tumour models could be harnessed to enhance the targeting of T cells towards tumours.
Overall, this study shows that our macaque model represents a useful model for studying tumour rejection, 
which will be exploited to develop new anticancer therapies. The chemokine receptor expression patterns of 
CD8+ TILs in this model provide insights into the molecular targets that promote T cell infiltration and accu-
mulation at the tumour site, which can be used to enhance the efficacy of adoptive immunotherapy for cancer.
Methods
Experimental animals and tumour transplantation. Cynomolgus macaques (Macaca fascicularis), 
both MHC homozygous and heterozygous for a particular set of Mafa haplotype alleles called HT1, were iden-
tified in the Filipino macaque population. The establishment of iPSCs from an MHC homozygous cynomolgus 
macaque, generation of iPSC-derived tumours cells (PTY cells) and transplantation of PTY cells to MHC hete-
rozygous cynomolgus macaques were performed as described in the previous study18. In one experiment, PTY 
cells were repeatedly transplanted into the same individual macaque. All protocols for animal experiments were 
approved by the Shiga University of Medical Science Animal Experiment Committee. This study was carried 
out in strict accordance with the Guidelines for the Husbandry and Management of Laboratory Animals of the 
Research Center for Animal Life Science at Shiga University of Medical Science and the Fundamental Guidelines 
for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the 
jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Cell preparation. Leukocytes were isolated from PB after the lysis of red blood cells with ammonium- 
chloride-potassium (ACK) buffer. For TIL isolation, removed tumours were weighed, minced and then incu-
bated in RPMI 1640 containing 2 mg/ml collagenase D (Roche) and 100 μg/ml DNase I (Roche) at 37 °C for 1 h. 
Digested samples were passed through a 70-μm nylon mesh twice and used as a mixture of TILs and tumour cells. 
The total cells were enumerated with a haemocytometer.
Flow cytometry. The monoclonal antibodies (mAbs) used for flow cytometric analyses were purchased from 
BD Biosciences, eBioscience or BioLegend, and included antibodies to CD3 (SP34-2), CD4 (OKT4), CD8 (SK1 or 
RPA-T8), CD16 (3G8), CD20 (2H7), CD45 (D058-1283), CD45RA (5H9), CD69 (FN50), CCR7 (G043H7), CXCR3 
(G025H7), granzyme B (GB11), IFN-γ (B27), IL-17A (BL168) and PD-1 (EH12.2H7). 7-Aminoactinomycin D 
(7-AAD) was used to distinguish between live and dead cells. Single-cell suspensions were incubated with human 
Fc receptor blocking reagent (Miltenyi Biotec) for 10 min, followed by staining with mAbs for 60 min on ice and 
washing. For intracellular cytokine staining, the cells were fixed and permeabilized using a BD Cytofix/Cytoperm 
Fixation/Permeabilization Kit. Data were acquired on a FACSAria or FACSCanto II (both from BD Biosciences) 
and analysed using FlowJo (Tree Star). From the total cell count and the percentage of each subset, the cell number 
of each subset was calculated. For sorting of CD4+ and CD8+ T cell subsets, lymphocytes were gated according to 
forward and side scatter from live (7-AAD−) CD45+ cells, and CD4+ T (CD3+CD4+CD8−CD20−) and CD8+ T 
(CD3+CD4−CD8+CD20−) cells were sorted from the lymphocyte gate using a FACSAria.
Quantitative PCR. Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse transcribed 
with a High Capacity RNA-to-cDNA Kit (Applied Biosystems). Quantitative real-time PCR was performed using 
KOD SYBR qPCR Mix (Toyobo) and a LightCycler 480 instrument (Roche). The primer pairs used are listed in 
Supplementary Table 1.
Received: 17 December 2019; Accepted: 4 May 2020;
Published: xx xx xxxx
References
 1. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 
6, 24–37 (2006).
 2. Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137–1146 (2007).
 3. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and 
combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016).
 4. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
 5. Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
 6. Dranoff, G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat. Rev. Immunol. 12, 
61–66 (2011).
 7. Carlsson, H. E., Schapiro, S. J., Farah, I. & Hau, J. Use of primates in research: a global overview. Am. J. Primatol. 63, 225–237 (2004).
 8. Sackstein, R., Schatton, T. & Barthel, S. R. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer 
immunotherapy. Lab. Invest. 97, 669–697 (2017).
 9. Amsen, D., van Gisbergen, K., Hombrink, P. & van Lier, R. A. W. Tissue-resident memory T cells at the center of immunity to solid 
tumors. Nat. Immunol. 19, 538–546 (2018).
 10. Smazynski, J. & Webb, J. R. Resident memory-like tumor-infiltrating lymphocytes (TILRM): latest players in the immuno-oncology 
repertoire. Front. Immunol. 9, 1741 (2018).
9Scientific RepoRtS |         (2020) 10:8414  | https://doi.org/10.1038/s41598-020-65488-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
 11. Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. Cancer Res. 74, 7168–7174 (2014).
 12. Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. 
Nat. Rev. Immunol. 17, 559–572 (2017).
 13. Mullins, I. M. et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients 
with stage III disease. Cancer Res. 64, 7697–7701 (2004).
 14. Mlecnik, B. et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. 
Gastroenterology 138, 1429–1440 (2010).
 15. Mikucki, M. E. et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular 
checkpoints. Nat. Commun. 6, 7458 (2015).
 16. Bronger, H. et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian 
cancer. Br. J. Cancer 115, 553–563 (2016).
 17. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. 
Nat. Rev. Cancer 12, 298–306 (2012).
 18. Ishigaki, H. et al. Transplantation of iPS-derived tumor cells with a homozygous MHC haplotype induces GRP94 antibody 
production in MHC-matched macaques. Cancer Res. 77, 6001–6010 (2017).
 19. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
 20. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
 21. Akari, H., Terao, K., Murayama, Y., Nam, K. H. & Yoshikawa, Y. Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys 
are of resting memory T lineage. Int. Immunol. 9, 591–597 (1997).
 22. Autissier, P., Soulas, C., Burdo, T. H. & Williams, K. C. Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in 
normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity. J. Immunol. Methods 360, 119–128 (2010).
 23. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and 
maintenance. Annu. Rev. Immunol. 22, 745–763 (2004).
 24. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 
3447–3452 (2016).
 25. Kansy, B. A. et al. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. 
Cancer Res. 77, 6353–6364 (2017).
 26. Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D. & Haribabu, B. Chemoattractant receptors BLT1 and CXCR3 regulate 
antitumor immunity by facilitating CD8+ T cell migration into tumors. J. Immunol. 197, 2016–2026 (2016).
 27. Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat. 
Immunol. 14, 1285–1293 (2013).
 28. Mackay, L. K. et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell 
retention. J. Immunol. 194, 2059–2063 (2015).
 29. Le Floc’h, A. et al. αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule 
polarization and exocytosis. J. Exp. Med. 204, 559–570 (2007).
 30. Franciszkiewicz, K. et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell 
retention. Cancer Res. 69, 6249–6255 (2009).
 31. Hombrink, P. et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat. Immunol. 
17, 1467–1478 (2016).
 32. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).
 33. Nam, K. et al. Peripheral blood extrathymic CD4+CD8+ T cells with high cytotoxic activity are from the same lineage as CD4+CD8− 
T cells in cynomolgus monkeys. Int. Immunol. 12, 1095–1103 (2000).
 34. Vujanovic, L. et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α. 
Front. Immunol. 10, 14 (2019).
Acknowledgements
This work was supported by the Research Fund Granted by the President of Shiga University of Medical Science.
Author contributions
H.S., H.I., K. Terada, Y.A., Y.I., K.O. and T.H. designed the experiment, H.S., H.I., K. Todo, K. Terada, Y.A., Y.I. 
and T.H. collected, analysed and interpreted the data, H.S. and T.H. wrote the manuscript, Y.A., Y.I., K.O. and T.H. 
provided financial support and all authors reviewed the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65488-x.
Correspondence and requests for materials should be addressed to T.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
